)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Lyra Therapeutics
Lyra Therapeutics (LYRA) investor relations material
Lyra Therapeutics has been otc
Lyra Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary31 Mar, 2026
Executive summary
Suspended all development of lead product LYR-210 for chronic rhinosinusitis in January 2026 after prior workforce reductions and cost-saving actions following mixed Phase 3 trial results.
Delisted from Nasdaq in March 2026 after ceasing operations and being deemed a public shell with no ongoing business activities.
Ongoing evaluation of strategic alternatives, including potential merger, sale, or liquidation, with no assurance of a transaction.
Financial highlights
Net loss for 2025 was $28.9 million, a significant improvement from $93.4 million in 2024, primarily due to reduced R&D and G&A expenses after restructuring.
Cash and cash equivalents at year-end 2025 were $15.9 million, down from $40.6 million at year-end 2024.
Operating expenses decreased to $31.4 million in 2025 from $97.9 million in 2024, reflecting lower clinical, personnel, and impairment costs.
No impairment charges in 2025; 2024 included $1.9 million for property/equipment and $22.8 million for right-of-use assets.
No product revenue; $0.4 million in collaboration revenue recognized in 2025 from the LianBio License Agreement.
Outlook and guidance
No intention to resume R&D activities unless a strategic transaction or significant new funding is secured.
Cash runway expected to last into Q3 2026, but subject to revision based on actual expenses and strategic outcomes.
Ongoing costs expected for strategic review, consulting, and public company compliance during wind-down.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lyra Therapeutics
- Proposals include director elections, auditor ratification, and a reverse stock split to maintain listing.LYRA
Proxy Filing - Key votes include director elections, auditor ratification, and a reverse stock split to support Nasdaq compliance.LYRAProxy Filing
- Key votes include director elections, auditor ratification, and a flexible reverse stock split.LYRAProxy Filing
- Alliance Advisors engaged for proxy solicitation at $18,000 for the 2025 annual meeting.LYRAProxy Filing
- Registering 846,744 shares for resale from warrants after positive Phase 3 CRS trial.LYRARegistration Filing
- Positive Phase 3 data and cost cuts, but urgent funding and Nasdaq risks remain.LYRAQ3 2025
- Net loss narrowed, costs cut, and strong Phase 3 data, but funding and regulatory risks remain.LYRAQ2 2025
- LYR-210 demonstrated strong Phase 3 efficacy and safety, advancing toward regulatory submission.LYRACorporate Presentation
- LYR-210 achieved significant efficacy and safety in ENLIGHTEN 2, supporting regulatory submission.LYRAStudy Result
Lyra Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Lyra Therapeutics Inc. is a clinical-stage biotechnology firm dedicated to developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). CRS is an inflammatory disease of the paranasal sinuses that results in prolonged periods of nasal congestion, facial pain, and nasal discharge. Leveraging expertise in materials science, drug development, and formulation, Lyra has introduced proprietary technology aimed at delivering medications directly, precisely, and consistently to the affected tissue for extended durations with a single administration. The company's leading product candidates include LYR-210 and LYR-220, both bioresorbable nasal implants designed for in-office procedures, intended to provide up to six months of continuous drug therapy to the sinonasal passages for CRS treatment. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq.